Sage Therapeutics stock drops
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer’s treatment
Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease failed to meet its main goal.
SAGE Therapeutics Inc (SAGE) Stock: Greater Than Its Current Valuation?
On Friday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.59 which represents a slight increase of $0.22 or 3.45% from the prior close of $6.37. The stock opened at $6.33 and touched a low of $6.
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment of mild cognitive
FierceBiotech5d
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington's
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
pharmaphorum4d
Sage takes another hit as Alzheimer's drug is canned
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
ETF Daily News2d
Sage Therapeutics (NASDAQ:SAGE) Rating Reiterated by Raymond James
Sage Therapeutics (NASDAQ:SAGE – Get Free Report)‘s stock had its “market perform” rating restated by analysts at Raymond James in a note issued to investors on Thursday, MarketBeat.com reports.
Business Insider3d
SAGE INVESTOR ALERT: Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
San Diego, California--(Newsfile Corp. - October 10, 2024) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between ...
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...
bovnews3d
How Does SAGE Therapeutics Inc (SAGE) Stack Up Against Its Industry Peers?
On Wednesday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.49 which represents a slight increase of $0.06 or 0.93% from the prior close of $6.43. The stock opened at $6 ...
SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Narrowed Success Prospects
SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues ...
Sage Therapeutics price target lowered to $8 from $9 at Wedbush
Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...
Zacks.com on MSN4d
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
Shares of Sage Therapeutics, Inc. SAGE were down 4.3% on Oct. 8 after the company announced disappointing top-line data from ...